動画検索
関連広告
検索結果
GRAND ROUNDS Hepatitis C Virus Remaining Challenges
HCV: Scope of the Problem 2021
Hepatitis C Virus Antiviral Drug Targets
A pangenotypic regimen for 8 weeks in compensated cirrhotic patients
Impact of SVR on Liver-related Mortality
The HCV Elimination Agenda
Access to therapy: Cost and Treaters as Barriers
Simplification: Primary Outcomes from the ACTG A5360 (MINMON) Study
Why the residual risk in HCV? possible mechanisms
Summary
Public Health Grand Rounds Resources
Global Burden of HCV Infection, 2005
Other Modes of HCV Transmission
HCV Testing Cost Effectiveness
Hepatitis C Treatment Responses Non-Response, Relapse, Sustained Viral Response
Reduction in All-Cause Mortality
Rapid Progress in Interferon-sparing HCV Treatment
Greater Uptake Will Maximize Potential Global Impact
Expanding Treatment in Primary Care to Meet Demand
Concerns and Research Needs for HCV TasP
Hepatitis C virus Is it a big deal?
It is a cancer-causing virus that kills over 400,000 people a year
One barrier to disease control? 4 out of 5 people with hepatitis C are not aware of their infection
Hepatitis C can be asymptomatic for years, so patients are often diagnosed late - if at all
Hepatitis C virus Diagnosis matters
Diagnosis of hepatitis C is vital. Finding 90% of those living with the disease is one of WHO'S 2030 elimination targets